Metabolomic therapy response prediction in pretherapeutic tissue biopsies for trastuzumab in patients with HER2‐positive advanced gastric cancer

QR Code

Metabolomic therapy response prediction in pretherapeutic tissue biopsies for trastuzumab in patients with HER2‐positive advanced gastric cancer

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Thomas Kunzke, Fabian T. Hölzl, Verena M. Prade, Achim Buck, Katharina Huber, Annette Feuchtinger, Karolin Ebert, Gwen Zwingenberger, Robert Geffers, Stefanie M. Hauck, Ivonne Haffner, Birgit Luber, Florian Lordick, Axel Walch
Format:	article
Langue:	EN
Publié:	Wiley 2021
Sujets:	Medicine (General) R5-920
Accès en ligne:	https://doaj.org/article/a209e45f32244846aabeedb91561d7bf
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer
par: Matteo Allegretti, et autres
Publié: (2021)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
par: Jamunarani Veeraraghavan, et autres
Publié: (2021)

Elbow Stiffness Imaging: A Practical Diagnostic and Pretherapeutic Approach
par: Charles Lombard, et autres
Publié: (2021)

Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
par: Oostra DR, et autres
Publié: (2014)

Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
par: Sawaki M
Publié: (2014)

Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas.
par: Sabina Berezowska, et autres
Publié: (2013)

An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy
par: Cedric Darini, et autres
Publié: (2019)

Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy
par: Patrícia M. R. Pereira, et autres
Publié: (2018)

Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab
par: Yousefpour P, et autres
Publié: (2011)

PTEN is a predictive biomarker of trastuzumab resistance and prognostic factor in HER2-overexpressing gastroesophageal adenocarcinoma
par: Daiju Yokoyama, et autres
Publié: (2021)

Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: Case report and review of the literature
par: Belal Firwana, et autres
Publié: (2012)

The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy.
par: Angelo Gámez-Pozo, et autres
Publié: (2014)

Combination of 131I-trastuzumab and lanatoside C enhanced therapeutic efficacy in HER2 positive tumor model
par: Nagarajan Vinod, et autres
Publié: (2021)

Combination of Near-Infrared Photoimmunotherapy Using Trastuzumab and Small Protein Mimetic for HER2-Positive Breast Cancer
par: Haruka Yamaguchi, et autres
Publié: (2021)

The efficacy of the combination of eribulin and trastuzumab in advanced HER2-positive breast cancer: the results of Russian observational study
par: Elena I. Kovalenko, et autres
Publié: (2020)

Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer
par: Laura M. Spring, et autres
Publié: (2021)

Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer
par: Azar I, et autres
Publié: (2021)

Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review
par: Linehan AS, et autres
Publié: (2021)

A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients
par: Huiping Li, et autres
Publié: (2018)

Influence of Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in early-stage HER2 positive breast cancer
par: Ljubica Vazdar, et autres
Publié: (2021)

Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data
par: Jagosky M, et autres
Publié: (2021)

Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab
par: Lize Wang, et autres
Publié: (2021)

The Role of Trastuzumab in Patients with HER2 Positive Small (pT1mi/a) Breast Cancers, a Multicenter Retrospective Study
par: Andrea Villasco, et autres
Publié: (2021)

Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer
par: Wengui Shi, et autres
Publié: (2021)

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial
par: Amy S. Clark, et autres
Publié: (2021)

Role in staging and prognostic value of pretherapeutic F-18 FDG PET/CT in patients with gastric MALT lymphoma without high-grade transformation
par: Yong-Jin Park, et autres
Publié: (2021)

2D-echocardiography vs cardiac MRI strain: a prospective cohort study in patients with HER2-positive breast cancer undergoing trastuzumab
par: Nathalie I. Bouwer, et autres
Publié: (2021)

Multimodal Imaging Technology Effectively Monitors HER2 Expression in Tumors Using Trastuzumab-Coupled Organic Nanoparticles in Patient-Derived Xenograft Mice Models
par: Li Wen, et autres
Publié: (2021)

Pathological Complete Response with Neoadjuvant Trastuzumab Combined with Chemotherapy in HER2 Positive Breast Cancer: A Single Institution Retrospective Analysis from Vietnam
par: Phung HT, et autres
Publié: (2020)

Towards integration of 64Cu-DOTA-trastuzumab PET-CT and MRI with mathematical modeling to predict response to neoadjuvant therapy in HER2 + breast cancer
par: Angela M. Jarrett, et autres
Publié: (2020)

A Case of Multiple Liver Metastases after Surgery in Elderly HER2-Positive Breast Cancer in Which Anastrozole + Trastuzumab Was Ineffective but T-DM1 Was Effective
par: Tomohiro Shidahara, et autres
Publié: (2021)

Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cells
par: Rodríguez-Serrano F, et autres
Publié: (2016)

Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)
par: Sara A. Hurvitz, et autres
Publié: (2020)

Investigation of antitumor activities of trastuzumab delivered by PLGA nanoparticles
par: Colzani B, et autres
Publié: (2018)

Efficacy with Trastuzumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutation in a Patient with a Poor Performance Status: A Case Report
par: Kato Y, et autres
Publié: (2021)

Molecular Progression of Myeloproliferative and Myelodysplastic/Myeloproliferative Neoplasms: A Study on Sequential Bone Marrow Biopsies
par: Magdalena M. Brune, et autres
Publié: (2021)

Native glycan fragments detected by MALDI mass spectrometry imaging are independent prognostic factors in pancreatic ductal adenocarcinoma
par: Na Sun, et autres
Publié: (2021)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
par: Avisek Majumder, et autres
Publié: (2021)

Reversible cardiotoxicity in a 54-year-old woman treated with trastuzumab
par: Martins,Sandro José, et autres
Publié: (2012)

Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution
par: Antolín S, et autres
Publié: (2018)